Acurx Pharmaceuticals, Inc. (ACXP)
$
5.05
-0.10 (-1.98%)
Key metrics
Financial statements
Free cash flow per share
-3.1 Thousand
Market cap
8 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
2.3400
Income quality
0.8467
Average inventory
0
ROE
-2.5242
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Acurx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing antibiotics to combat bacterial infections. The company has incurred an interest expense of $0.00 reflecting its debt servicing obligations as it advances its lead antibiotic candidate, ibezapolstat. This novel drug utilizes a unique mechanism of action that targets the polymerase IIIC enzyme and has successfully completed Phase II clinical trials aimed at treating patients afflicted with clostridium difficile infections. The operating income ratio is 0.00 indicating the company's operational profitability margin, while the EBITDA ratio is 0.00 highlighting its operational efficiency. For the fiscal year 2024 the weighted average number of shares outstanding is 808,150.00 showcasing the company's commitment to its shareholder base. Additionally, Acurx is developing ACX-375C, a potential treatment designed for both oral and parenteral delivery that targets gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Incorporated in 2017, the company is headquartered in Staten Island, New York. The stock is affordable at $0.46 making it suitable for budget-conscious investors looking for opportunities in the biopharmaceutical sector. However, the stock has a low average trading volume of 331,541.00 indicating lower market activity, which may affect liquidity for potential investors. With a market capitalization of $8,003,139.00 the company is classified as a small-cap player within the competitive landscape. Acurx Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market dynamic and driving forward innovation and growth. It belongs to the Healthcare sector, where it plays an essential role in advancing antibiotic solutions and addressing pressing healthcare needs.
Is Acurx Pharmaceuticals, Inc. (ACXP) a good investment?
Investing in Acurx Pharmaceuticals, Inc. (ACXP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Acurx Pharmaceuticals, Inc. (ACXP)'s stock forecast?
Analysts predict Acurx Pharmaceuticals, Inc. stock to fluctuate between $3.80 (low) and $47.80 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Acurx Pharmaceuticals, Inc.'s market capitalization?
As of 2025-08-20, Acurx Pharmaceuticals, Inc.'s market cap is $8,003,139, based on 1,584,780 outstanding shares.
How does Acurx Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Acurx Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Acurx Pharmaceuticals, Inc. (ACXP) stock?
To buy Acurx Pharmaceuticals, Inc. (ACXP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACXP. Place an order (Market, Limit, etc.).
What is the best time to invest in Acurx Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Acurx Pharmaceuticals, Inc. stock ever split?
Acurx Pharmaceuticals, Inc.'s last stock split was 1:20 on 2025-08-05.
How did Acurx Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$17,450.80 | Growth: 75,740.07%.
Where can I find Acurx Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.acurxpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Acurx Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Acurx Pharmaceuticals, Inc. stock?
All-time high: $8.82 (2023-10-12) | All-time low: $0.29 (2025-08-01).
What are the key trends affecting Acurx Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
STATEN ISLAND, N.Y. , Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2025.
prnewswire.com
Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025 STATEN ISLAND, N.Y. , July 31, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the board of directors of the Company approved a 1-for-20 reverse stock split (the "Reverse Split") of the Company's common stock.
zacks.com
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
prnewswire.com
STATEN ISLAND, N.Y. , June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per share, resulting in gross proceeds of approximately $2.67 million, before deducting offering fees and other expenses payable by the Company.
seekingalpha.com
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and CFO David Luci - President and CEO Conference Call Participants Joanne Lee - Maxim Group James Molloy - Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 Financial Results and Business Update. At this time, all participants are in a listen-only mode.
prnewswire.com
STATEN ISLAND, N.Y. , May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.
prnewswire.com
STATEN ISLAND, N.Y. , April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open.
zacks.com
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
seekingalpha.com
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Thomas Yip - H.C. Wainwright James Molloy - Alliance Global Partners Claire Acheson - Independent Investment Research Operator Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results and Business Update.
prnewswire.com
STATEN ISLAND, N.Y. , March 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 2,745,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.40 per share (or per common stock equivalent in lieu thereof).
See all news
